Efficacy and Safety of Depemokimab Monotherapy Without Concomitant Use of Intranasal Corticosteroids (INCS) in Japanese Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

NCT07701967 ↗

Phase 4 Not yet recruiting 28 enrolled GlaxoSmithKline

NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the efficacy and safety of depemokimab (GSK3511294) without concomitant use of Intranasal corticosteroids (INCS) in participants with Chronic rhinosinusitis with nasal polyps (CRSwNP).

Timeline

Start: 2026-07-20
Primary completion: 2027-07-01
Completion: 2028-06-16

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Depemokimab	Protein / enzyme biologic	100 mg	Subcutaneous

Efficacy and Safety of Depemokimab Monotherapy Without Concomitant Use of Intranasal Corticosteroids (INCS) in Japanese Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Summary

Timeline

Drugs

Indications